Development of cancer immunotherapy using tumor-associated antigen-derived long peptides and liberation from immune suppression mediated trough IL-6 signaling

• Project/Area Number: 15H04311
• Research Category: Grant-in-Aid for Scientific Research (B)
• Allocation Type: Single-year Grants
• Section: 一般
• Research Field: Tumor therapeutics
• Research Institution: Kumamoto University
• Principal Investigator: Nishimura Yasuharu 熊本大学, 生命資源研究・支援センター, シニア教授 (10156119)
• Co-Investigator(Kenkyū-buntansha): 入江 厚 熊本大学, 大学院生命科学研究部(医), 講師 (30250343) ; 河野 健司 大阪府立大学, 工学(系)研究科(研究院), 教授 (90215187)
• Co-Investigator(Renkei-kenkyūsha): Eto Masatoshi 九州大学, 大学院医学研究院, 教授 (90315078) ; Nakayama Hideki 熊本大学, 大学院生命科学研究部, 教授 (70381001)
• Research Collaborator: Tsukamoto Hirotake (Awai Hirotake) 熊本大学, 大学院生命科学研究部, 講師 (10433020)
• Project Period (FY): 2015-04-01 – 2018-03-31
• Project Status: Completed (Fiscal Year 2017)
• Budget Amount: ¥16,770,000 (Direct Cost: ¥12,900,000、Indirect Cost: ¥3,870,000); Fiscal Year 2017: ¥3,380,000 (Direct Cost: ¥2,600,000、Indirect Cost: ¥780,000); Fiscal Year 2016: ¥6,370,000 (Direct Cost: ¥4,900,000、Indirect Cost: ¥1,470,000); Fiscal Year 2015: ¥7,020,000 (Direct Cost: ¥5,400,000、Indirect Cost: ¥1,620,000)
• Keywords: 腫瘍免疫 / 腫瘍関連抗原 / 抗原ペプチド / 細胞傷害性T細胞 / ヘルパーT細胞 / IL-6シグナル / 免疫抑制的腫瘍微小環境 / 免疫抑制解除 / がん免疫療法 / 腫瘍関連抗原ペプチド / 細胞傷害性Ｔ細胞 / 免疫抑制 / IL-6 シグナル / ＨＬＡ / がん抗原ワクチン / 長鎖がん抗原ペプチド / 免疫抑制解除療法 / 癌抗原 / 癌抗原ワクチン / 長鎖癌抗原ペプチド

Outline of Final Research Achievements

We previously identified novel tumor-associated antigens (TAAs) frequently overexpressed in various cancers. In this study we identified these TAAs-derived long peptides (LPs) that can induce both Th1 cells restricted by common HLA class II molecules, and tumor-reactive CTLs specific to SPs included in LPs by cross-presentation in both human in vitro culture and HLA-transgenic mice in vivo. These LPs were naturally presented by DC and these TAA-LPs-specific Th cells were observed in cancer patients suggesting usefulness of these peptides for cancer immunotherapy. We demonstrated that tumor-specific Th1 cells was attenuated in tumor-bearing mice and cancer patients in an IL-6 and soluble IL-6 receptor (sIL-6R)-dependent manner. Abundant IL-6/sIL-6R was produced by myeloid cells in tumor-bearing mice and inhibition of IL-6-mediated signals restored the T cell-mediated tumor immunity suggesting that IL-6/sIL-6R is a rational target to augment T-cell-mediated cancer immunotherapy.

Research Products

• [Int'l Joint Research] Univ. Massachusetts Medical School(米国)
• [Journal Article] Bladder cancer-associated cancer-testis antigen-derived long peptides encompassing both CTL and promiscuous HLA class II-restricted Th cell epitopes induced CD4+ T cells expressing converged T-cell receptor genes in vitro (2018)
  • Author(s): Tsuruta Miki、Ueda Shohei、Yew Poh Yin、Fukuda Isao、Yoshimura Sachiko、Kishi Hiroyuki、Hamana Hiroshi、Hirayama Masatoshi、Yatsuda Junji、Irie Atsushi、Senju Satoru、Yuba Eiji、Kamba Tomomi、Eto Masatoshi、Nakayama Hideki、Nishimura Yasuharu
  • Journal Title: OncoImmunology Volume: 7 Issue: 4 Pages: 1415687-1415687
  • DOI: 10.1080/2162402x.2017.1415687
  • Peer Reviewed / Open Access
• [Journal Article] Soluble IL-6R expressed by myeloid cells reduces tumor-specific Th1 differentation and drives tumor progression (2017)
  • Author(s): Tsukamoto H, Fujieda K, Hirayama M, Ikeda T, Yuno A, Matsumura K, Fukuma D, Araki K, Mizuta H, Nakayama H, Senju S, Nishimura Y
  • Journal Title: Cancer Research Volume: 14 Issue: 9 Pages: 2279-2291
  • DOI: 10.1158/0008-5472.can-16-2446
  • Peer Reviewed / Open Access
• [Journal Article] Immune-suppressive effects of interleukin-6 on T-cell-mediated anti-tumor immunity (2017)
  • Author(s): Tsukamoto Hirotake、Fujieda Koji、Senju Satoru、Ikeda Tokunori、Oshiumi Hiroyuki、Nishimura Yasuharu
  • Journal Title: Cancer Science Volume: 109 Issue: 3 Pages: 523-530
  • DOI: 10.1111/cas.13433
  • Peer Reviewed / Open Access
• [Journal Article] An oncofetal antigen, IMP-3-derived long peptides induce immune responses of both helper T cells and CTLs (2016)
  • Author(s): M. Hirayama, Y. Tomita, A. Yuno, H. Tsukamoto, S. Sejju, Y. Imamura, M. A. Sayem, A. Irie, Y. Yoshitake, D. Fukuma, M. Shinohara, A. Hamada, H. Jono, E. Yuba, K. Kono, K. Yoshida, T. Tsunoda, H. Nakayama, Y. Nishimura
  • Journal Title: OncoImmunology Volume: 5 Issue: 6 Pages: e1123368-e1123368
  • DOI: 10.1080/2162402x.2015.1123368
  • Peer Reviewed / Open Access / Int'l Joint Research
• [Journal Article] The present status and future prospects of peptide-based cancer vaccines. (2016)
  • Author(s): Hirayama M, Nishimura Y
  • Journal Title: Int Immunol Volume: 28 Issue: 7 Pages: 319-328
  • DOI: 10.1093/intimm/dxw027
  • Peer Reviewed / Open Access
• [Journal Article] Generation of Large Numbers of Antigen-Expressing Human Dendritic Cells Using CD14-ML Technology (2016)
  • Author(s): Yuya Imamura, Miwa Haruta, Yusuke Tomita, Keiko Matsumura, Tokunori Ikeda, Akira Yuno1, Masatoshi Hirayama, Hideki Nakayama, Hiroshi Mizuta, Yasuharu Nishimura, Satoru Senju
  • Journal Title: Plos One Volume: 11 Issue: 4 Pages: e0152384-e0152384
  • DOI: 10.1371/journal.pone.0152384
  • Peer Reviewed / Open Access / Acknowledgement Compliant
• [Journal Article] がん抗原ワクチン療法の現状と展望 (2016)
  • Author(s): 平山真敏、西村泰治
  • Journal Title: 実験医学（羊土社） 「がん免疫療法 腫瘍免疫学の最新知見から治療法のアップデートまで」 Volume: 第34巻 増刊 Pages: 148-155
• [Journal Article] Identification of glypican-3-derived long peptides activating both CD8 and CD4 T cells; prolonged overall survival in cancer patients with Th cell response (2016)
  • Author(s): Sayem, M. A. Tomita, Y. Yuno, A. Hirayama, M. Irie, A. Tsukamoto, H. Senju, S. Yuba, E. Yoshikawa, T. Kono, K. Nakatsura, T. Nishimura, Y.
  • Journal Title: Oncoimmunology Volume: 5 Issue: 1 Pages: e1062209-e1062209
  • DOI: 10.1080/2162402x.2015.1062209
  • Peer Reviewed / Open Access / Int'l Joint Research
• [Journal Article] がん抗原ワクチン療法の現状と展望 (2016)
  • Author(s): 平山真敏、西村泰治
  • Journal Title: 医学のあゆみ（医歯薬出版株式会社） Volume: 256 Pages: 817-822
• [Journal Article] IL-6-mediated environmental conditioning of defective Th1 differentiation dampens anti-tumor immune responses in old age. (2015)
  • Author(s): Tsukamoto, H., Senju, S., Matsumura, K., Swain, S.L., and Nishimura, Y.
  • Journal Title: Nature Communications Volume: 6 Issue: 1 Pages: 6702-6702
  • DOI: 10.1038/ncomms7702
  • Peer Reviewed / Open Access / Int'l Joint Research
• [Journal Article] A clinical trial of multiple peptides vaccination for advanced head and neck cancer patients induced immune responses and prolonged OS. (2015)
  • Author(s): Yoshitake, Y., Nishimura Y., Nakamura Y., and Shinohara, M.
  • Journal Title: OncoImmunology Volume: 4 Issue: 8 Pages: e1022307-e1022307
  • DOI: 10.1080/2162402x.2015.1022307
  • Peer Reviewed
• [Journal Article] Cancer immunotherapy using novel tumor-associated antigenic peptides identified by genome-wide cDNA microarray analyses (2015)
  • Author(s): Nishimura, Y., Tomita, Y., Yuno, A., Yoshitake, Y., Shinohara, M.
  • Journal Title: Cancer Science Volume: 106 Issue: 5 Pages: 505-511
  • DOI: 10.1111/cas.12650
  • Peer Reviewed / Open Access / Acknowledgement Compliant
• [Journal Article] がんワクチン療法の現状と展望 (2015)
  • Author(s): 平山真敏、西村泰治
  • Journal Title: メディカル・サイエンス・ダイジェスト（ニューサイエンス社） Volume: 41 Pages: 19-22
• [Presentation] Identification of bladder cancer-associated cancer-testis antigens-derived long peptides encompassing both CTL and promiscuous HLA class II-restricted Th cell epitopes (2018)
  • Author(s): Nishimura Y, Tsuruta M, Ueda S, Poh Yin Yew PY, Fukuda I, Yoshimura S, Kishi H, Hamana H, Hirayama M, Yatsuda J, Irie A, Senju S, Yuba E, Kamba T, Eto M, Nakayama H
  • Organizer: The American Association for Cancer Research (AACR) Annual Meeting 2018
  • Int'l Joint Research
• [Presentation] A possible Th1 cell-activating combination cancer immunotherapy using active immunization and IL-6 signaling blockade (2017)
  • Author(s): 2.Tsukamoto H, Tsuruta M, Hirayama M, Senju S, Nakayama H and Nishimura Y
  • Organizer: The 36th Sapporo International Cancer Symposium
  • Int'l Joint Research / Invited
• [Presentation] Identification of bladder cancer-associated cancer-testis antigens-derived long peptides encompassing both CTL and promiscuous HLA class II-restricted Th1 cell epitopes (2017)
  • Author(s): 3.Tsuruta M, Hirayama M, Ueda S, Yatsuda J, Irie A, Senju S, Kamba T, Eto M, Nakayama H and Nishimura Y
  • Organizer: The 36th Sapporo International Cancer Symposium
  • Int'l Joint Research
• [Presentation] 免疫抑制因子としての IL-6シクグナルを標的とした抗腫瘍免疫応答予測と、IL-6/PD-L1 阻害併用療法の有効性の検討 (2017)
  • Author(s): 4.塚本 博丈、藤枝 浩司、福島 聡、池田 徳典、宮下 梓、久保 陽介、千住 覚、尹 浩信、押海 裕之、西村 泰治
  • Organizer: 第21回日本がん免疫学会総会
• [Presentation] 2種類の膀胱癌関連がん精巣抗原に由来する長鎖ペプチドにより誘導されるCTL/TH1細胞とTCRの解析 (2017)
  • Author(s): 5.鶴田 未季、上田 翔平、平山 真敏、矢津田 旬二、入江 厚、千住 覚、江藤 正俊、中山 秀樹、西村 泰治
  • Organizer: 第21回日本がん免疫学会総会
• [Presentation] がん免疫療法を理解するための基礎免疫学 (2017)
  • Author(s): 西村 泰治
  • Organizer: 第76回日本癌学会学術総会
  • Invited
• [Presentation] 腫瘍免疫学とがん免疫療法のブレークスルー (2017)
  • Author(s): 西村 泰治
  • Organizer: 第27回国際喘息学会日本・北アジア部会
  • Int'l Joint Research / Invited
• [Presentation] 膀胱癌関連がん精巣抗原由来の長鎖ペプチドに特異的なHLA拘束性T細胞の免疫応答とTCRの解析 (2017)
  • Author(s): 9.鶴田 未季、上田 翔平、平山 真敏、矢津田 旬二、入江 厚、千住 覚、神波 大己、江藤 正俊、中山 秀樹、西村 泰治
  • Organizer: 第26回日本組織適合性学会大会
• [Presentation] T細胞による抗腫瘍免疫応答の基礎 (2017)
  • Author(s): 西村 泰治
  • Organizer: 第30回日本バイオセラピィ学会学術集会総会
  • Invited
• [Presentation] Is there a revival of the cancer vaccine? (2016)
  • Author(s): Yasuharu Nishimura
  • Organizer: Educational Session: What you should know about cancer immunotherapy, The European Society of Medical Oncology (ESMO) Asia
  • Place of Presentation: Suntec Singapore Convention & Exhibition Centre （シンガポール）
  • Year and Date: 2016-12-16
  • Int'l Joint Research / Invited
• [Presentation] Identification of cancer-testis antigen (DEPDC1 and MPHOSPH1)-derived long peptides encompassing both CTL and HLA class II-restricted Th cell epitopes. (2016)
  • Author(s): Miki Nakane, Masatoshi Hirayama, Shohei Ueda, Mohammad Abu Sayem, Junji Yatsuda, Atsushi Irie, Satoru Senju, Masatoshi Eto, Hideki Nakayama and Yasuharu Nishimura
  • Organizer: 第45回 日本免疫学会学術集会
  • Place of Presentation: 沖縄コンベンションセンター （沖縄県 宜野湾市）
  • Year and Date: 2016-12-05
• [Presentation] HLA 拘束性 T 細胞を活性化するがん抗原ペプチドワクチンの開発 (2016)
  • Author(s): 西村 泰治、平山 真敏、Mohammad Abu Sayem、湯野 晃、冨田 雄介、今村 悠哉、千住 覚、塚本 (粟井) 博丈、入江 厚、河野 健司、吉武 義泰、中村 祐輔、中面 哲也、篠原 正徳、中山 秀樹
  • Organizer: シンポジウム ３ [基礎] MHCを視点とした免疫異常・感染症治療戦略の新展開、第25回 日本組織適合性学会大会
  • Place of Presentation: 北海道大学学術交流会館 （北海道 札幌市）
  • Year and Date: 2016-10-22
  • Invited
• [Presentation] Next generation combined cancer vaccines. (2016)
  • Author(s): Yasuharu Nishimura, Masatoshi Hirayama, Mohammad Abu Sayem, Yuya Imamura, Satoru Senju, Akira Yuno, Yusuke Tomita, Yoshihiro Yoshitake, Kenji Kawano, Tetsuya Nakatsura, Yusuke Nakamura, Masanori Shinohara and Hideki Nakayama.
  • Organizer: The Core Symposia 2 "Beyond the immune checkpoint blockade", The 75th Annual Meeting of Japanese Association of Cancer.
  • Place of Presentation: Pacifico Yokohama （神奈川県 横浜市）
  • Year and Date: 2016-10-06
  • Invited
• [Presentation] がん免疫療法の画期的なブレークスルー (2016)
  • Author(s): 西村泰治
  • Organizer: 第8回名古屋臨床薬理セミナー
  • Place of Presentation: ウェスティンナゴヤキャッスル（名古屋市）
  • Year and Date: 2016-02-03
  • Invited
• [Presentation] がん免疫療法の画期的なブレークスルー (2015)
  • Author(s): 西村泰治
  • Organizer: 第30回日本生殖免疫学会総会・学術集会
  • Place of Presentation: くまもと県民交流館パレア
  • Year and Date: 2015-11-21
  • Invited
• [Presentation] Prolonged overall survival in hepatocellular carcinoma patients vaccinated with glupican-3 CTL epitopes and exhibiting glypican-3-specific Th cell responses (2015)
  • Author(s): Sayem Mohammad Abu, Tomita Yusuke, Hirayama Masatoshi, Tsukamotmo Hirotake, Senju Satoru, Nakatsura Tetsuya, Nishimura Yasuharu
  • Organizer: 第44回日本免疫学会総会・学術集会
  • Place of Presentation: 札幌コンベンションセンター（札幌市）
  • Year and Date: 2015-11-18
• [Presentation] ヒトT細胞の抗原認識と免疫応答の解析－その疾患感受性解析と免疫療法開発への応用 (2015)
  • Author(s): 西村泰治
  • Organizer: 第44回日本免疫学会総会・学術集会
  • Place of Presentation: 札幌コンベンションセンター（札幌市）
  • Year and Date: 2015-11-18
  • Invited
• [Presentation] 肝細胞癌の免疫療法への応用を目指した長鎖Glypican-3ペプチドの同定 (2015)
  • Author(s): 西村泰治
  • Organizer: 第53回日本癌治療学会学術集会
  • Place of Presentation: 国立京都国際会館（京都市）
  • Year and Date: 2015-10-29
  • Invited
• [Presentation] CTLとTh1細胞の誘導活性を併せ持つ癌胎児性抗原IMP-3由来のロングペプチドの同定 (2015)
  • Author(s): 平山真敏、冨田雄介、湯野晃、Abu Sayem Mohammad、塚本博丈、千住覚、福間大喜、弓場英司、河野健司、吉田浩二、中村祐輔、中山秀樹、西村泰治
  • Organizer: 第74回日本癌学会学術総会
  • Place of Presentation: 名古屋国際会議場（名古屋市）
  • Year and Date: 2015-10-08
• [Presentation] がん免疫療法の画期的なブレイクスルー (2015)
  • Author(s): 西村泰治
  • Organizer: 第74回日本癌学会学術総会
  • Place of Presentation: 名古屋国際会議場（名古屋市）
  • Year and Date: 2015-10-08
  • Invited
• [Presentation] 主要組織適合性抗原に対するアロ反応性の基礎免疫学 (2015)
  • Author(s): 西村泰治
  • Organizer: 第51回日本移植学会総会
  • Place of Presentation: ホテル日航熊本（熊本市）
  • Year and Date: 2015-10-01
  • Invited
• [Presentation] HLA拘束性T細胞を活性化するがん抗原ペプチドワクチンの臨床研究 (2015)
  • Author(s): 西村泰治、Mohammad Abu Sayem、平山真敏、吉武義泰、河野健司、中村祐輔、中面哲也、篠原正徳
  • Organizer: 第24回日本組織適合性学会大会
  • Place of Presentation: ホテルレイクビュー水戸（水戸市）
  • Year and Date: 2015-09-10
  • Invited
• [Presentation] 癌胎児性抗原IMP-3由来のCTLとTh1細胞の誘導活性を併せ持つ、多様なHLAクラスII拘束性の長鎖癌抗原ペプチドの同定 (2015)
  • Author(s): 平山真敏、冨田雄介、湯野晃、Mohammad Abu Sayem、千住覚、入江厚、塚本博丈、中根未季、弓場英司、河野健司、吉田浩二、中村祐輔、中山秀樹、西村泰治
  • Organizer: 第24回日本組織適合性学会大会
  • Place of Presentation: ホテルレイクビュー水戸（水戸市
  • Year and Date: 2015-09-10
• [Presentation] Identification of oncofetal antigen (IMP-3)-derived long peptides encompassing both CTL epitopes and multiple HLA class II-restricted Th cell epitopes (2015)
  • Author(s): Hirayama, M., Tomita, Y., Yuno, A., Sayem M.A., Nakane, M., Tsukamoto, H., Irie, A., Senju, S., Yoshitake, Y., Fukuma, D., Shinohara, M., Yuba, E., Kono, K., Yoshida, K., Nakamura, Y., Nakayama, H., Nishimura, Y.
  • Organizer: International Conference of Cancer Immunotherapy and Macrophages 2015
  • Place of Presentation: Ito Hall, Ito International Research Center, The University of Tokyo, Tokyo
  • Year and Date: 2015-07-09
  • Int'l Joint Research
• [Presentation] Identification of oncofetal antigen Glypican-3-derived long peptides encompassing CTL and multiple HLA class II-restricted Th cell epitopes (2015)
  • Author(s): Sayem M.A., Tomita, Y., Yuno, A., Hirayama, M., Yuba, E., Kono, K., Yoshikawa, T., Nakatsura, T., Nishimura, Y.
  • Organizer: 13th CIMT (Cancer Immunotherapy) Annual Meeting
  • Place of Presentation: Rheingold Halle Congress Center, Germany
  • Year and Date: 2015-05-11
  • Int'l Joint Research
• [Book] 標準免疫学 第3版 第2編 第5章 G. ＭＨＣの構造と機能 (2018)
  • Author(s): 塚本 博丈、西村 泰治
  • Total Pages: 7
  • Publisher: 医学書院
• [Book] 標準免疫学 第3版 第2編 第5章 H. 抗原提示のメカニズム (2018)
  • Author(s): 入江 厚、西村 泰治
  • Total Pages: 6
  • Publisher: 医学書院
• [Book] MHC 第25巻1号 がん免疫療法におけるがん抗原ワクチン療法の現状と展望 (2018)
  • Author(s): 鶴田 未季、西村 泰治
  • Total Pages: 10
  • Publisher: 日本組織適合性学会
• [Book] 炎症と免疫 第26巻3号 次世代がん抗原ワクチン (2018)
  • Author(s): 鶴田 未季、西村 泰治
  • Total Pages: 6
  • Publisher: 先端医学社
• [Book] Tips on Immuno-Oncology がん免疫療法に重要な「抗原認識」と「腫瘍抗原」を理解する (2017)
  • Author(s): 西村 泰治
  • Total Pages: 5
  • Publisher: 医科学出版社
• [Book] 遺伝子医学 MOOK３１号 CTLとTh細胞を共に活性化できるがんペプチドワクチン療法の開発 (2017)
  • Author(s): 平山 真敏、西村 泰治
  • Total Pages: 7
  • Publisher: メデイカルドウ社
• [Remarks] 熊本大学 大学院生命科学研究部 免疫識別学分野 ホームページ
  • URL: http://www.immgenet.jp/
• [Patent(Industrial Property Rights)] DEPDC1 EPITOPE PEPTIDES FOR TH1 CELLS AND VACCINES CONTAINING THE SAME (2016)
  • Inventor(s): 西村 泰治、平山 真敏、中根 未季、山下（吉村）祥子
  • Industrial Property Rights Holder: 西村 泰治、平山 真敏、中根 未季、山下（吉村）祥子
  • Industrial Property Rights Type: 特許
  • Industrial Property Number: 2016-224624
  • Filing Date: 2016-11-18
  • Overseas
• [Patent(Industrial Property Rights)] MPHOSPH1 EPITOPE PEPTIDES FOR TH1 CELLS AND VACCINES CONTAINING THE SAME (2016)
  • Inventor(s): 西村 泰治、平山 真敏、中根 未季、山下（吉村）祥子
  • Industrial Property Rights Holder: 西村 泰治、平山 真敏、中根 未季、山下（吉村）祥子
  • Industrial Property Rights Type: 特許
  • Industrial Property Number: 2016-224625
  • Filing Date: 2016-11-18
  • Overseas
• [Patent(Industrial Property Rights)] IMP-3 EPITOPE PEPTIDES FOR TH1 CELLS AND VACCINES CONTAINING THE SAME (2015)
  • Inventor(s): 西村泰治, 冨田雄介, 平山 真敏, 大沢龍司
  • Industrial Property Rights Holder: オンコセラピー・サイエンス株式会社
  • Industrial Property Rights Type: 特許
  • Filing Date: 2015
  • Acquisition Date: 2017
  • Overseas
• [Patent(Industrial Property Rights)] LY6K EPITOPE PEPTIDES FOR TH1 CELLS AND VACCINES CONTAINING THE SAME (2015)
  • Inventor(s): 西村泰治, 冨田雄介, 大沢龍司
  • Industrial Property Rights Holder: オンコセラピー・サイエンス株式会社
  • Industrial Property Rights Type: 特許
  • Filing Date: 2015
  • Acquisition Date: 2017
  • Overseas
• [Patent(Industrial Property Rights)] KIF20A EPITOPE PEPTIDES FOR TH1 CELLS AND VACCINES CONTAINING THE SAME (2015)
  • Inventor(s): 西村泰治, 冨田雄介, 大沢龍司
  • Industrial Property Rights Holder: オンコセラピー・サイエンス株式会社
  • Industrial Property Rights Type: 特許
  • Filing Date: 2015
  • Acquisition Date: 2017
  • Overseas
• [Patent(Industrial Property Rights)] CDCA1 EPITOPE PEPTIDES FOR TH1 CELLS AND VACCINES CONTAINING THE SAME (2015)
  • Inventor(s): 西村泰治, 冨田雄介, 大沢龍司
  • Industrial Property Rights Holder: オンコセラピー・サイエンス株式会社
  • Industrial Property Rights Type: 特許
  • Filing Date: 2015
  • Acquisition Date: 2017
  • Overseas
• [Patent(Industrial Property Rights)] GPC3 EPITOPE PEPTIDES FOR TH1 CELLS AND VACCINES CONTAINING THE SAME (2015)
  • Inventor(s): 西村泰治, 冨田雄介, 大沢龍司
  • Industrial Property Rights Holder: オンコセラピー・サイエンス株式会社
  • Industrial Property Rights Type: 特許
  • Filing Date: 2015-12-04
  • Overseas